Preliminary study on albuvirtide as conversion therapy for HIV-infected patients with low viral reservoir

Phase 4, open-label, single-arm trial of albuvirtide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by The Second Hospital of Nanjing. Primary endpoint: Proportion of patients with plasma HIV RNA load < 50 copies/mL. Planned start Aug 2021; status: not yet recruiting.